Analysis of Clinical Data on the Treatment of Type 2 Diabetes with BMPRP

<i>Objective:</i> This study aims to comprehensively analyze the factors influencing the efficacy of bone marrow platelet-rich plasma (BMPRP) therapy in patients with type 2 diabetes mellitus. <i>Methods: </i>In this clinical investigation, autologous bone marrow was harvested from participants, followed by the isolation of BMPRP. Patients then underwent ultrasound-guided infusion of BMPRP directly into the pancreas. The follow-up period for evaluating treatment outcomes spanned one year, during which various factors potentially affecting the therapeutic effects were systematically analyzed. <i>Results: </i>A total of 49 patients diagnosed with type 2 diabetes mellitus received BMPRP pancreatic infusion as a treatment modality. Among these patients, 32 demonstrated a positive response to the therapy, while 17 experienced no significant improvement. Notably, in the effective treatment group, fasting blood glucose levels exhibited a significant reduction after one month of intervention. Additionally, glycosylated hemoglobin (HbA1c) levels showed a substantial decrease at the three-month mark, and a gradual decline in insulin dosage requirements was observed over time. In contrast, changes in C-peptide levels were not pronounced. Analysis of the ineffective treatment group revealed that these patients often had obesity, demonstrated minimal physical activity, and did not adhere to dietary recommendations for carbohydrate control. <i>Conclusion:</i> The findings suggest that BMPRP pancreatic infusion can improve pancreatic function and glycemic control in type 2 diabetes patients. However, for optimal outcomes, it is crucial to combine this therapy with a regimen that includes regular exercise and strict management of carbohydrate intake. This multifaceted approach promises to enhance the effectiveness of BMPRP therapy and contribute to better overall management of type 2 diabetes.